Oxidative metabolic pathway of lenvatinib mediated by aldehyde oxidase

Drug Metabolism and Disposition

Volumn 42, Issue 8, 2014, Pages 1326-1333

  Inoue, Kazuko ^a   Mizuo, Hitoshi ^a   Kawaguchi, Shinki ^a   Fukuda, Katsuyuki ^a   Kusano, Kazutomi ^a   Yoshimura, Tsutomu ^a  

^a EISAI CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE OXIDASE; CIMETIDINE; CYTOCHROME P450; LENVATINIB; PROTEIN TYROSINE KINASE INHIBITOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; VASCULOTROPIN RECEPTOR; ZALEPLON; 4-(3-CHLORO-4-(N'-CYCLOPROPYLUREIDO)PHENOXY)-7-METHOXYQUINOLINE-6-CARBOXAMIDE; CARBANILAMIDE DERIVATIVE; QUINOLINE DERIVATIVE;

AEROBIC METABOLISM; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOG; DRUG ELIMINATION; DRUG METABOLISM; DRUG STRUCTURE; ENZYME KINETICS; ENZYME METABOLISM; ENZYME SUBSTRATE; HAPLORHINI; HUMAN; LIVER CYTOSOL; MALE; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; CYTOSOL; DRUG DETOXIFICATION; ENZYMOLOGY; KINETICS; LIVER; LIVER MICROSOME; MACACA FASCICULARIS; METABOLISM; OXIDATION REDUCTION REACTION; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ALDEHYDE OXIDASE; ANIMALS; CYTOSOL; DOGS; HUMANS; KINETICS; LIVER; MACACA FASCICULARIS; MALE; METABOLIC DETOXICATION, PHASE I; MICROSOMES, LIVER; OXIDATION-REDUCTION; PHENYLUREA COMPOUNDS; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84904172747     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.058073     Document Type: Article

References (19)

1. Akabane T, Tanaka K, Irie M, Terashita S, and Teramura T (2011) Case report of extensive metabolism by aldehyde oxidase in humans: pharmacokinetics and metabolite profile of FK3453 in rats, dogs, and humans. Xenobiotica 41:372-384.
2. Austin NE, Baldwin SJ, Cutler L, Deeks N, Kelly PJ, Nash M, Shardlow CE, Stemp G, Thewlis K, and Ayrton A, et al. (2001) Pharmacokinetics of the novel, high-affinity and selective dopamine D3 receptor antagonist SB-277011 in rat, dog and monkey: in vitro/in vivo correlation and the role of aldehyde oxidase. Xenobiotica 31:677-686. (Pubitemid 32826399)
3. Beedham C, Critchley DJP, and Rance DJ (1995) Substrate specificity of human liver aldehyde oxidase toward substituted quinazolines and phthalazines: a comparison with hepatic enzyme from guinea pig, rabbit, and baboon. Arch Biochem Biophys 319:481-490.
4. Boss DS, Glen H, Beijnen JH, Keesen M, Morrison R, Tait B, Copalu W, Mazur A, Wanders J, and O'Brien JP, et al. (2012) A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. Br J Cancer 106:1598-1604.
5. Diamond S, Boer J, Maduskuie TP, Jr, Falahatpisheh N, Li Y, and Yeleswaram S (2010) Species-specific metabolism of SGX523 by aldehyde oxidase and the toxicological implications. Drug Metab Dispos 38:1277-1285.
6. Ghafourian T and Rashidi MR (2001) Quantitative study of the structural requirements of phthalazine/quinazoline derivatives for interaction with human liver aldehyde oxidase. Chem Pharm Bull (Tokyo) 49:1066-1071. (Pubitemid 32847508)
7. Hutzler JM, Obach RS, Dalvie D, and Zientek MA (2013) Strategies for a comprehensive understanding of metabolism by aldehyde oxidase. Expert Opin Drug Metab Toxicol 9:153-168.
8. Houston JB and Kenworthy KE (2000) In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab Dispos 28:246-254. (Pubitemid 30137047)
9. 14)C]lenvatinib after oral administration to male cynomolgus monkey. Drug Metab Dispos 40:662-670.
10. Kawashima K, Hosoi K, Naruke T, Shiba T, Kitamura M, and Watabe T (1999) Aldehyde oxidase-dependent marked species difference in hepatic metabolism of the sedative-hypnotic, zaleplon, between monkeys and rats. Drug Metab Dispos 27:422-428. (Pubitemid 29114253)
11. Kitamura S, Sugihara K, and Ohta S (2006) Drug-metabolizing ability of molybdenum hydroxylases. Drug Metab Pharmacokinet 21:83-98.
12. Kola I and Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nature Rev 3:711-715. (Pubitemid 39173511)
13. Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, and Asada M (2008a) Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 14:5459-5465.
14. Matsui J, Yamamoto Y, Funahashi Y, Tsuruoka A, Watanabe T, Wakabayashi T, Uenaka T, and Asada M (2008b) E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer 122:664-671. (Pubitemid 350308963)
15. Obach RS (2004) Potent inhibition of human liver aldehyde oxidase by raloxifene. Drug Metab Dispos 32:89-97.
16. Okamoto K, Kodama K, Takase K, Sugi NH, Yamamoto Y, Iwata M, and Tsuruoka A (2013) Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett 340:97-103.
17. Pryde DC, Dalvie D, Hu Q, Jones P, Obach RS, and Tran T-D (2010) Aldehyde oxidase: an enzyme of emerging importance in drug discovery. J Med Chem 53:8441-8460.
18. Renwick AB, Ball SE, Tredger JM, Price RJ, Walters DG, Kao J, Scatina JA, and Lake BG (2002) Inhibition of zaleplon metabolism by cimetidine in the human liver: in vitro studies with subcellular fractions and precision-cut liver slices. Xenobiotica 32:849-862. (Pubitemid 35155520)
19. Sahi J, Khan KK, and Black CB (2008) Aldehyde oxidase activity and inhibition in hepatocytes and cytosolic fractions from mouse, rat, monkey and human. Drug Metab Lett 2:176-183.